Skip to content

Turkish Validation of the Rapprich Lipedema Symptomatic Assessment Questionnaire

Turkish Validity and Reliability of the Rapprich Lipedema Symptomatic Assessment Questionnaire

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07725146
Acronym
RapprichTR
Enrollment
180
Registered
2026-07-24
Start date
2026-07-17
Completion date
2027-03-15
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipedema

Keywords

Lipedema, Rapprich Questionnaire, Symptom Assessment, Turkish, Cultural Adaptation, Adipose Tissue Diseases, Quality of Life

Brief summary

Lipedema is a chronic disease characterized by abnormal fat accumulation, primarily in the lower extremities, affecting women. This study aims to evaluate the validity and reliability of the Turkish version of the Rapprich Lipedema Symptomatic Assessment Questionnaire, which was originally developed by Rapprich et al. in 2010. Since a validated Turkish version is currently unavailable, this research will provide a standardized tool for clinicians to assess symptomatic severity in Turkish-speaking lipedema patients.

Detailed description

This cross-sectional study will involve 180 female participants diagnosed with lipedema (Stages I, II, and III). Participants will be recruited from the Physical Medicine and Rehabilitation clinics of Marmara University and Sultan 2. Abdülhamid Han Training and Research Hospital. Assessments will include: * Demographic data (age, BMI). * Physical examinations (waist-hip ratio, limb circumference, and volume calculations). * Functional testing (6-minute walk test). * The Turkish version of the Rapprich Lipedema Symptomatic Assessment -Questionnaire (15 items scored 0-10). * The SF-36 Health Survey for criterion validity. Statistical analysis will include Cronbach's alpha for internal consistency, Intraclass Correlation Coefficient (ICC) for test-retest reliability (14-day interval), and Exploratory/Confirmatory Factor Analysis for construct validity.

Interventions

OTHERPhysical Examination and Functional Testing

* Anthropometric and Vital Measurements: Recording of demographic data (age, height, weight, BMI), as well as arterial blood pressure and pulse rate. * Lipedema-Specific Assessment: Clinical determination of the lipedema stage (Stages I-III) and type (Types I-V). * Morphometric Measurements: Measurement of waist and hip circumferences (for waist-to-hip ratio) and actual leg length. * Lower Extremity Volume Calculation: Circular circumference measurements taken at 4 cm intervals starting from the ankle to calculate the total volume of both lower extremities. * 6-Minute Walk Test (6MWT): A functional test to evaluate the total walking distance and heart rate response, assessing the patient's functional capacity.

OTHERQuestionnaires

Turkish version of Rapprich Lipedema Symptomatic Assessment Questionnaire: A 15-item scale used to evaluate the severity of lipedema symptoms (such as pain, tension, tenderness, bruising, and heaviness) on a 0-10 point rating scale. Short Form-36 (SF-36) Health Survey: A widely used, validated scale to assess the general health status and quality of life across eight sub-dimensions, used in this study for criterion validity

Sponsors

Marmara University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Female patients aged 18-75. * Diagnosed with lipedema by a clinician. * Willingness to participate and sign the informed consent form.

Exclusion criteria

* Positive Stemmer sign or presence of advanced-stage lymphedema. * Diagnosis of Heart Failure. * Chronic Kidney Disease. * Pregnancy. * BMI \> 50 kg/m².

Design outcomes

Primary

MeasureTime frameDescription
Internal Consistency (Cronbach's Alpha)At baseline (Day 0).Evaluation of the internal consistency of the 15-item Turkish Rapprich Lipedema Questionnaire.

Secondary

MeasureTime frameDescription
Test-Retest Reliability (ICC)Baseline and 14 daysAgreement between two measurements taken 14 days apart in a subgroup of 40 patients.
Criterion Validity (Correlation with SF-36).At baseline (Day 0)Correlation between Rapprich questionnaire scores and the 8 sub-dimensions of the SF-36 quality of life scale.

Countries

Turkey (Türkiye)

Contacts

CONTACTCanan Şanal, Assoc. Prof.
canansanal@hotmail.com+90 533 138 10 32
CONTACTM. Selim Eryılmaz, Res. Asst.
PRINCIPAL_INVESTIGATORCanan Şanal, Assoc. Prof.

Marmara University Faculty of Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026